This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
SARTORIUS (SARTF) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
SARTORIUS (SARTF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
SARTORIUS (SARTF) Q3 Earnings Lag Estimates
by Zacks Equity Research
SARTORIUS (SARTF) delivered earnings and revenue surprises of -23.65% and 3.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
SARTORIUS (SARTF) Surges 7.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
SARTORIUS (SARTF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
SARTORIUS (SARTF) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
SARTORIUS (SARTF) delivered earnings and revenue surprises of 7.39% and 7.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Dynatronics Corporation (DYNT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of -11.11% and 0.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SARTORIUS (SARTF) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
SARTORIUS (SARTF) delivered earnings and revenue surprises of 6.56% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SARTORIUS (SARTF) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
SARTORIUS (SARTF) delivered earnings and revenue surprises of 10.04% and 8.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Avinger (AVGR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avinger (AVGR) delivered earnings and revenue surprises of 0% and 4.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
SARTORIUS (SARTF) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
SARTORIUS (SARTF) delivered earnings and revenue surprises of 1.24% and 1.82%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Looking for a Growth Stock? 3 Reasons Why SARTORIUS (SARTF) is a Solid Choice
by Zacks Equity Research
SARTORIUS (SARTF) possesses solid growth attributes, which could help it handily outperform the market.
Phirbo (PAHC) Q1 Earnings Lag Estimates, Revenue View Up
by Zacks Equity Research
Phirbo's (PAHC) year-over-year increase in Q1 sales is primarily due to stronger international demand for poultry and cattle products and more robust growth in the nutritional specialties and vaccine product lines.
Illumina (ILMN) Q3 Earnings Top Estimates, 2021 Revenue View Up
by Zacks Equity Research
Illumina (ILMN) exited the third quarter with better-than-expected results on strength in Core Illumina and the newly-acquired GRAIL businesses.
Amedisys (AMED) Tops Q3 Earnings Estimates, Slashes '21 View
by Zacks Equity Research
Amedisys (AMED) reports better-than-expected earnings for the third quarter on strong growth in the Home Health segment.
Charles River (CRL) Q3 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
Charles River (CRL) exited the third quarter of 2021 with better-than-expected earnings on strength in the RMS, DSA and Manufacturing Solutions arms driving the top line.
IDEXX (IDXX) Q3 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
IDEXX's (IDXX) Q3 top line rides on strong sales at the CAG and Water businesses.
Bruker (BRKR) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Bruker (BRKR) reports better-than-expected earnings and revenues for the third quarter of 2021 on geographical performance driving the top line.
Chemed (CHE) Q3 Earnings Beat Estimates, Full-Year EPS View Up
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings and revenues in the third-quarter 2021, with a solid performance by the Roto-Rooter segment driving the top line.
ResMed (RMD) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
ResMed (RMD) reports better-than-expected earnings and revenues with robust demand for sleep and respiratory care devices driving Q1 top line.
Teleflex (TFX) Q3 Earnings Top Estimates, Full-Year EPS View Up
by Zacks Equity Research
Teleflex (TFX) reports better-than-expected earnings and revenues with strong geographical performance driving the top line in third-quarter 2021.
3 Reasons Why SARTORIUS (SARTF) Is a Great Growth Stock
by Zacks Equity Research
SARTORIUS (SARTF) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SARTORIUS (SARTF) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
SARTORIUS (SARTF) delivered earnings and revenue surprises of 7.59% and 5.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
SARTORIUS (SARTF) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
SARTORIUS (SARTF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SARTORIUS AG (SARTF) Surges 3.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
SARTORIUS AG (SARTF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here is Why Growth Investors Should Buy SARTORIUS AG (SARTF) Now
by Zacks Equity Research
SARTORIUS AG (SARTF) is well positioned to outperform the market, as it exhibits above-average growth in financials.